î
îŒ
î
Spero Therapeutics Inc
SPRO2.365USD
+0.045+1.94%
ååŒæé ïŒETïŒ15åé
ãã®æ ªäŸ¡
133.18Mæ䟡ç·é¡
æ倱é¡çŽè¿12ã¶æPER
î
詳现æ å ± Spero Therapeutics Inc äŒæ¥å
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.
Spero Therapeutics Incã®äŒæ¥æ å ±
îäŒæ¥ã³ãŒãSPRO
äŒç€ŸåSpero Therapeutics Inc
äžå Žæ¥Nov 02, 2017
æé«çµå¶è²¬ä»»è
ãCEOãRajavelu (Esther)
åŸæ¥å¡æ°32
蚌åžçš®é¡Ordinary Share
決ç®ææ«Nov 02
æ¬ç€Ÿæåšå°675 Massachusetts Ave Ste 14
éœåžCAMBRIDGE
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·02139-3309
é»è©±çªå·18572421600
ãŠã§ããµã€ãhttps://sperotherapeutics.com/
äŒæ¥ã³ãŒãSPRO
äžå Žæ¥Nov 02, 2017
æé«çµå¶è²¬ä»»è
ãCEOãRajavelu (Esther)
Spero Therapeutics Incã®çµå¶é£
îäŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Dr. Ankit Mahadevia, M.D.
Dr. Ankit Mahadevia, M.D.
Non-Executive Director
Non-Executive Director
364.22K
-1.77%
Ms. Esther Rajavelu
Ms. Esther Rajavelu
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
188.41K
-17.61%
Mr. Timothy (Tim) Keutzer
Mr. Timothy (Tim) Keutzer
Chief Operating Officer
Chief Operating Officer
145.31K
-1.15%
Dr. Milind S. Deshpande, Ph.D.
Dr. Milind S. Deshpande, Ph.D.
Independent Director
Independent Director
91.45K
+27.99%
Ms. Kathleen Tregoning
Ms. Kathleen Tregoning
Independent Director
Independent Director
75.00K
+36.36%
Ms. Cynthia Smith
Ms. Cynthia Smith
Independent Director
Independent Director
75.00K
+36.36%
Mr. Frank E. Thomas, CPA
Mr. Frank E. Thomas, CPA
Independent Chairman of the Board
Independent Chairman of the Board
75.00K
+36.36%
Dr. Patrick Volkert Jozef Johannes Vink, M.D.
Dr. Patrick Volkert Jozef Johannes Vink, M.D.
Lead Independent Director
Lead Independent Director
--
--
Mr. Scott T. Jackson
Mr. Scott T. Jackson
Independent Director
Independent Director
--
--
Dr. John C. Pottage, Jr., M.D.
Dr. John C. Pottage, Jr., M.D.
Independent Director
Independent Director
--
--
äŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Dr. Ankit Mahadevia, M.D.
Dr. Ankit Mahadevia, M.D.
Non-Executive Director
Non-Executive Director
364.22K
-1.77%
Ms. Esther Rajavelu
Ms. Esther Rajavelu
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
188.41K
-17.61%
Mr. Timothy (Tim) Keutzer
Mr. Timothy (Tim) Keutzer
Chief Operating Officer
Chief Operating Officer
145.31K
-1.15%
Dr. Milind S. Deshpande, Ph.D.
Dr. Milind S. Deshpande, Ph.D.
Independent Director
Independent Director
91.45K
+27.99%
Ms. Kathleen Tregoning
Ms. Kathleen Tregoning
Independent Director
Independent Director
75.00K
+36.36%
Ms. Cynthia Smith
Ms. Cynthia Smith
Independent Director
Independent Director
75.00K
+36.36%
åçå èš³
é貚: USDæŽæ°æå»: Mon, Oct 6
é貚: USDæŽæ°æå»: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
äºæ¥å¥USD
äŒç€Ÿå
åç
æ¯ç
Collaboration Revenue Related Party
11.80M
83.18%
Grant Revenue
2.39M
16.82%
Collaboration Revenue
0.00
0.00%
å°åå¥USD
äŒç€Ÿå
åç
æ¯ç
United States
14.19M
100.00%
äºæ¥å¥
å°åå¥
äºæ¥å¥USD
äŒç€Ÿå
åç
æ¯ç
Collaboration Revenue Related Party
11.80M
83.18%
Grant Revenue
2.39M
16.82%
Collaboration Revenue
0.00
0.00%
æ ªäž»
æŽæ°æå»: Tue, Dec 2
æŽæ°æå»: Tue, Dec 2
æ ªäž»çµ±èš
çš®é¡
æ ªäž»çµ±èš
æ ªäž»çµ±èš
æ¯ç
GSK plc
16.31%
Pfizer Inc
4.19%
The Vanguard Group, Inc.
3.53%
Anson Funds Management LP.
2.85%
Renaissance Technologies LLC
2.58%
ä»ã®
70.54%
æ ªäž»çµ±èš
æ ªäž»çµ±èš
æ¯ç
GSK plc
16.31%
Pfizer Inc
4.19%
The Vanguard Group, Inc.
3.53%
Anson Funds Management LP.
2.85%
Renaissance Technologies LLC
2.58%
ä»ã®
70.54%
çš®é¡
æ ªäž»çµ±èš
æ¯ç
Corporation
20.51%
Hedge Fund
6.15%
Investment Advisor
5.58%
Investment Advisor/Hedge Fund
2.52%
Individual Investor
2.43%
Venture Capital
1.64%
Research Firm
0.20%
Bank and Trust
0.02%
ä»ã®
60.96%
æ©é¢æè³å®¶ä¿ææ ª
îæŽæ°æå»: Wed, Oct 1
æŽæ°æå»: Wed, Oct 1
å ±åæé
æ©é¢æè³å®¶æ°
ä¿ææ ªåŒæ°
æ¯ç
å€åé¡
2025Q3
106
9.05M
16.08%
-5.89M
2025Q2
114
26.06M
46.61%
-2.84M
2025Q1
116
27.38M
49.07%
-1.56M
2024Q4
125
27.51M
50.50%
+2.91M
2024Q3
143
24.19M
44.62%
-8.19M
2024Q2
160
25.74M
47.53%
-7.31M
2024Q1
203
25.36M
47.08%
-8.60M
2023Q4
209
24.88M
47.35%
-1.62M
2023Q3
223
24.62M
47.01%
-2.06M
2023Q2
230
24.99M
47.83%
-1.96M
詳现ãèŠã
æ ªäž»åå
îäŒç€Ÿå
ä¿ææ ªåŒæ°
æ¯ç
å€åé¡
å€åç
æ¥ä»
GSK plc
9.19M
16.33%
--
--
Mar 27, 2025
Pfizer Inc
2.36M
4.2%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
1.95M
3.47%
+186.76K
+10.59%
Jun 30, 2025
Anson Funds Management LP.
1.62M
2.87%
-2.18M
-57.48%
Jun 30, 2025
Renaissance Technologies LLC
832.16K
1.48%
-138.74K
-14.29%
Jun 30, 2025
Alphabet, Inc.
889.98K
1.58%
--
--
Jun 30, 2025
Geode Capital Management, L.L.C.
510.70K
0.91%
-14.17K
-2.70%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
433.55K
0.77%
-39.27K
-8.31%
Jun 30, 2025
Mahadevia (Ankit)
364.22K
0.65%
-6.57K
-1.77%
Aug 28, 2025
The Informed Momentum Company LLC
239.14K
0.42%
+239.14K
--
Jun 30, 2025
詳现ãèŠã
é¢é£ETF
îæŽæ°æå»: Sat, Dec 6
æŽæ°æå»: Sat, Dec 6
éæå
æ¯ç
Invesco NASDAQ Future Gen 200 ETF
0.63%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
0%
Invesco NASDAQ Future Gen 200 ETF
æ¯ç0.63%
Avantis US Small Cap Equity ETF
æ¯ç0%
iShares Micro-Cap ETF
æ¯ç0%
é åœé
îéå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã
æ¥ä»
é
åœé
æš©å©ç¢ºå®æ¥
æ¯ææ¥
é
åœèœã¡æ¥
ããŒã¿ãªã
æ ªåŒåå²
îæ¥ä»
çš®é¡
æ¯ç
ããŒã¿ãªã
æ¥ä»
çš®é¡
æ¯ç
ããŒã¿ãªã
ãããã質å
Spero Therapeutics Incã®äžäœ5åã®æ ªäž»ã¯èª°ã§ããïŒ
îSpero Therapeutics Incã®äžäœ5åã®æ ªäž»ã¯ä»¥äžã®ãšããã§ãã
GSK plcã¯9.19Mæ ªãä¿æããŠãããããã¯å šäœã®16.33%ã«çžåœããŸãã
Pfizer Incã¯2.36Mæ ªãä¿æããŠãããããã¯å šäœã®4.20%ã«çžåœããŸãã
The Vanguard Group, Inc.ã¯1.95Mæ ªãä¿æããŠãããããã¯å šäœã®3.47%ã«çžåœããŸãã
Anson Funds Management LP.ã¯1.62Mæ ªãä¿æããŠãããããã¯å šäœã®2.87%ã«çžåœããŸãã
Renaissance Technologies LLCã¯832.16Kæ ªãä¿æããŠãããããã¯å šäœã®1.48%ã«çžåœããŸãã
GSK plcã¯9.19Mæ ªãä¿æããŠãããããã¯å šäœã®16.33%ã«çžåœããŸãã
Pfizer Incã¯2.36Mæ ªãä¿æããŠãããããã¯å šäœã®4.20%ã«çžåœããŸãã
The Vanguard Group, Inc.ã¯1.95Mæ ªãä¿æããŠãããããã¯å šäœã®3.47%ã«çžåœããŸãã
Anson Funds Management LP.ã¯1.62Mæ ªãä¿æããŠãããããã¯å šäœã®2.87%ã«çžåœããŸãã
Renaissance Technologies LLCã¯832.16Kæ ªãä¿æããŠãããããã¯å šäœã®1.48%ã«çžåœããŸãã
Spero Therapeutics Incã®æ ªäž»ã¿ã€ãäžäœ3çš®ã¯äœã§ããïŒ
îSpero Therapeutics Incã®æ ªäž»ã¿ã€ãäžäœ3çš®ã¯ã
GSK plc
Pfizer Inc
The Vanguard Group, Inc.
GSK plc
Pfizer Inc
The Vanguard Group, Inc.
Spero Therapeutics IncïŒSPROïŒã®æ ªåŒãä¿æããŠããæ©é¢ã®æ°ã¯ããã€ã§ããïŒ
î2025Q3æç¹ã§ãSpero Therapeutics Incã®æ ªåŒãä¿æããŠããæ©é¢ã¯106瀟ãããä¿ææ ªåŒã®ç·åžå ŽäŸ¡å€ã¯çŽ9.05Mã§ãå
šäœã®16.08%ãå ããŠããŸãã2025Q2ãšæ¯èŒããŠãæ©é¢ã®æã¡æ ªã¯-30.53%å¢å ããŠããŸãã
Spero Therapeutics Incã®æ倧ã®åçæºã¯äœã§ããïŒ
îFY2025Q2ã«ãããŠãCollaboration Revenue Related PartyéšéãSpero Therapeutics Incã«ãšã£ãŠæ倧ã®åçãçã¿åºããŠããããã®éé¡ã¯11.80Mã§ãå
šåçã®83.18%ãå ããŠããŸãã
